Unknown

Dataset Information

0

Depiction of Branched-Chain Amino Acids (BCAAs) in Diabetes with a Focus on Diabetic Microvascular Complications.


ABSTRACT: Type 2 diabetes mellitus (T2DM) still holds the title as one of the most debilitating chronic diseases with rising prevalence and incidence, including its complications such as retinal, renal, and peripheral nerve disease. In order to develop novel molecules for diagnosis and treatment, a deep understanding of the complex molecular pathways is imperative. Currently, the existing agents for T2DM treatment target only blood glucose levels. Over the past decades, specific building blocks of proteins-branched-chain amino acids (BCAAs) including leucine, isoleucine, and valine-have gained attention because they are linked with insulin resistance, pre-diabetes, and diabetes development. In this review, we discuss the hypothetical link between BCAA metabolism, insulin resistance, T2DM, and its microvascular complications including diabetic retinopathy and diabetic nephropathy. Further research on these amino acids and their derivates may eventually pave the way to novel biomarkers or therapeutic concepts for the treatment of diabetes and its accompanied complications.

SUBMITTER: Tanase DM 

PROVIDER: S-EPMC10531730 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Depiction of Branched-Chain Amino Acids (BCAAs) in Diabetes with a Focus on Diabetic Microvascular Complications.

Tanase Daniela Maria DM   Gosav Evelina Maria EM   Botoc Tina T   Floria Mariana M   Tarniceriu Claudia Cristina CC   Maranduca Minela Aida MA   Haisan Anca A   Cucu Andrei Ionut AI   Rezus Ciprian C   Costea Claudia Florida CF  

Journal of clinical medicine 20230919 18


Type 2 diabetes mellitus (T2DM) still holds the title as one of the most debilitating chronic diseases with rising prevalence and incidence, including its complications such as retinal, renal, and peripheral nerve disease. In order to develop novel molecules for diagnosis and treatment, a deep understanding of the complex molecular pathways is imperative. Currently, the existing agents for T2DM treatment target only blood glucose levels. Over the past decades, specific building blocks of protein  ...[more]

Similar Datasets

| S-EPMC8999875 | biostudies-literature
| S-EPMC10711269 | biostudies-literature
| S-EPMC5478300 | biostudies-literature
| S-EPMC11626946 | biostudies-literature
| S-EPMC9259854 | biostudies-literature
| S-EPMC10100834 | biostudies-literature
| S-EPMC4717153 | biostudies-literature
| 2744698 | ecrin-mdr-crc
| S-EPMC3756605 | biostudies-literature
| S-EPMC11434239 | biostudies-literature